Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria
Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria have?
Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria has 33 citations in the OpenAlex counts ScholarIQ stores.
When was Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria published?
Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria has 2018 year in the ScholarIQ index.
What is the open-access status of Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria?
Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria has hybrid oa status in the ScholarIQ index.
What is the DOI of Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria?
The DOI for Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria is on the source record.
What is the PMID of Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria?
The PMID for Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria is on the source record.
What is the OpenAlex record for Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria?
The OpenAlex for Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria is on the source record.